Background
Charcot-Marie-Tooth type 1A (CMT1A) is an autosomal dominant polyneuropathy due to a 1.5 Mb tandem duplication in chromosome
17p11.2, containing the PMP22 gene. This mutation is not modified during inheritance.
Objectives
We set forth to test the hypothesis that in a subgroup of CMT1A patients there is clinical anticipation, namely an increase
in disease severity over generations.
Methods
Thirty-nine CMT1A mutation-positive patients in 16 families and 23 parent-offspring pairs were evaluated. This included 14
families with 2 generations and 2 families with 3 generations. Age of presentation was assessed by interviewing the patients
and clinical severity was measured using the CMT neuropathy score (CMTNS).
Results
In 21/23 parent-child pairs and 14/16 families, there was an earlier age of presentation in children of genetically affected
parents. The mean age of onset in the progeny was 12.61 years compared to 41.22 years in the parent generation, (p < 0.001).Mean
severity in the younger generation was slightly higher than that of the parent generation. When corrected for the age difference,
the trend for a worse phenotype in the younger generation became statistically significant (p < 0.02,Wilcoxon signed rank
test).
Conclusions
Our findings suggest that in a subgroup of CMT1A patients there is an increase in clinical severity over generations. The
mechanism responsible for this observation remains unknown. Our findings should be validated on a larger cohort of CMT1A families.
Key words Charcot-Marie-Tooth 1A - hereditary neuropathy - anticipation - CMT neuropathy score - age of symptom onset